Although some prior studies demonstrated a change of SUV in response to chemotherapy as a predictive factor in aggressive breast cancer, such as the HER2 subtype [28], few studies have evaluated the predictive value of the pSUVmax in response to chemotherapy only in HR-positive, HER2-negative breast cancer patients. Here, ERBB2 is linked to breast carcinoma.